Covid-19 vaccine makers told Congress on Feb. 23 that U.S. supplies should surge in the coming weeks due to manufacturing expansions and new vaccine authorizations.

French healthcare company Sanofi will provide Covid-19 vaccine manufacturing support to U.S. peer Johnson & Johnson.

Shares of Endo International were up after announcing positive earnings and a new restructuring plan that is expected to “optimize” the company’s operations through the elimination of several manufacturing sites and the employees who work there.

The Covid-19 pandemic changed the biopharma industry and the world irrevocably, and the challenges will reverberate even after the pandemic ends, according to some health experts.

Grand River Aseptic Manufacturing (GRAM) inked a deal with Janssen Pharmaceutical to support the manufacturing of the Johnson & Johnson company’s Covid-19 vaccine candidate.

In anticipation of data from a Phase III vaccine candidate study potentially becoming available in October, Germany’s BioNTech acquired a manufacturing facility from Novartis to boost production capabilities for the preventative treatment for the novel coronavirus.

Although it’s increasingly likely that one of the Covid-19 vaccines being tested will be approved or receive Emergency Use Authorization (EUA) before the end of 2020, experts are increasingly warning that widespread distribution may take a much longer time.

Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement with AstraZeneca to support the development of a vaccine against Covid-19.

The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.

Merck CEO Ken Frazier says the first vaccines against Covid-19, should they meet the 50 percent efficacy threshold set by the U.S. Food and Drug Administration, may not have as broad of an impact as hoped.